Drug updated on 9/4/2024
Dosage Form | Tablet (oral: 200 mg, 400 mg) |
Drug Class | Sodium-glucose co-transporter 2 inhibitors |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure.
- Indicated to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors.
Latest News
Summary
- Inpefa (sotagliflozin) is indicated to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure. It also aims to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors.
- This summary is based on the review of 17 systematic review(s)/meta-analysis(es). [1-17]
- Cardiovascular Mortality and Hospitalizations: Sotagliflozin significantly reduced cardiovascular mortality, hospitalizations, and urgent heart failure (HF) visits in patients with HF compared to dapagliflozin, particularly in those with higher initial symptom burden. SGLT2 inhibitors, including sotagliflozin, also significantly improved cardiovascular outcomes, with no significant differences observed among dapagliflozin, empagliflozin, and sotagliflozin in composite outcomes of cardiovascular death or hospitalization for HF.
- Composite Cardiovascular Outcomes: Sotagliflozin significantly improved the composite outcome of cardiovascular death or hospitalization for HF. Additionally, canagliflozin, dapagliflozin, empagliflozin, and sotagliflozin significantly reduced major adverse cardiovascular events (MACE) and hospitalization for HF.
- Quality of Life: Sotagliflozin increased the number of days alive and out of the hospital (DAOH) in HF patients, enhancing patient-centered outcomes. SGLT2 inhibitors, including sotagliflozin, were also associated with improved quality of life in HF patients.
- Renal Composite Outcomes: Sotagliflozin, along with other SGLT2 inhibitors like dapagliflozin and empagliflozin, significantly reduced the risk of renal composite outcomes.
- Sotagliflozin significantly increased the risk of genital mycotic infections in patients with both T1DM and T2DM, as well as the risk of acidosis-related adverse events, including diabetic ketoacidosis (DKA), particularly in T1DM patients.
- Sotagliflozin was associated with an increased risk of diarrhea, volume depletion, and severe hypoglycemia, with the latter being more pronounced compared to pure SGLT2 inhibitors.
- Comparative safety analysis showed no major differences in safety outcomes between sotagliflozin and empagliflozin, canagliflozin, or dapagliflozin, although dapagliflozin may have a lower risk of severe hypoglycemia.
- The evidence shows that SGLT2 inhibitors, including sotagliflozin, were studied in specific populations such as those with heart failure (HF), including HF with preserved ejection fraction (HFpEF) and mildly reduced ejection fraction (HFmrEF), as well as patients with type 1 and type 2 diabetes mellitus (T1DM and T2DM), and those with cardiovascular and renal conditions. Key findings include a significant reduction in cardiovascular death, hospitalization for HF, and improved quality of life in HF patients, improved cardiovascular and renal outcomes in T2DM patients, and an increased risk of acidosis-related events and hypoglycemia in T1DM patients.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Inpefa (sotagliflozin) Prescribing Information. | 2024 | Lexicon Pharmaceuticals, Inc., The Woodlands, TX |
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
Document Title | Year | Source |
---|---|---|
Practical guidance for the use of SGLT2 inhibitors in heart failure. | 2023 | American Journal of Cardiovascular Drugs |
Sodium-glucose co-transporter 2 inhibitors in heart failure: an updated evidence-based practical guidance for clinicians. | 2023 | European Heart Journal Supplements |
Sodium-glucose co-transporter 2 inhibitors in acute heart failure: a review of the available evidence and practical guidance on clinical use. | 2022 | Reviews in Cardiovascular Medicine |
2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. | 2022 | Journal of the American College of Cardiology |
Sodium-glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction. | 2022 | European Journal of Heart Failure |